Abu-Qurain Hawra, Almashhad Fatimah, Lucca Jisha M, Abumadini Mahdi Saeed
Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisl University, Dammam, Kingdom of Saudi Arabia.
Department of Psychiatry, College of Medicine Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
J Pharm Bioallied Sci. 2020 Jul-Sep;12(3):351-355. doi: 10.4103/jpbs.JPBS_368_19. Epub 2020 Jul 18.
Therapeutic drug monitoring (TDM) is the widely used tool in neuropsychiatric disorders. It is a valuable tool for tailoring the dose, preventing adverse drug reactions, and testing the drug adherence, therapeutic nonresponse, pharmacokinetic, and drug-drug interactions. TDM is most useful for individualized pharmacotherapy in bipolar disorders. But there exists a death of information on TDM of mood stabilizers in real-life scenario. Hence, this study aimed to assess the use and indication of TDM for mood stabilizers in a university hospital.
A descriptive, retrospective, study was carried in a university teaching hospital in Dammam metropolitan region of Saudi Arabia. Patients were included in the study if they had a mood stabilizer with serum level drawn between January 2017 to December 2018. The patient list was collected from "QuadraMed" health information system. TDM details such as values of each TDM, reason for the TDM, and number of TDM for 1 year have been documented.
A total of 200 patients received 242 mood stabilizers during the study period. Gender distribution was almost equal in the study population male (52%) versus female (48%). Average age of the patients was 40 years (range = 17-87 years). A total of 41.5% ( = 83) patients were diagnosed with bipolar type 1. Valproic acid ( = 139 [57.9%]) and lithium ( = 54 [22.3%]) were the most commonly used mood stabilizers. Majority (80%) of the bipolar patients were managed with single mood stabilizers. A total of 613 TDM was ordered for the 200 patients during the study period. The average number of TDM per patient during the study period was 3 (range = 1-39). Validation of the therapeutic level ( = 140), lack of clinical response ( = 51), and change in the dose ( = 34) are the documented reasons for TDM.
This study highlights the common and specific reasons for TDM of mood stabilizers in routine clinical practice. More extensive study on a larger sample size in the prospective basis is required to find out the rationality of TDM orders and its outcome for the development of the polices.
治疗药物监测(TDM)是神经精神疾病中广泛使用的工具。它是调整剂量、预防药物不良反应以及检测药物依从性、治疗无反应性、药代动力学和药物相互作用的重要工具。TDM在双相情感障碍的个体化药物治疗中最为有用。但在现实生活场景中,关于心境稳定剂的TDM信息匮乏。因此,本研究旨在评估某大学医院中心境稳定剂TDM的使用情况及适应证。
在沙特阿拉伯达曼大都会地区的一所大学教学医院开展了一项描述性回顾性研究。纳入2017年1月至2018年12月期间进行过血清水平检测的使用心境稳定剂的患者。患者名单从“QuadraMed”健康信息系统收集。记录了TDM的详细信息,如每次TDM的值、TDM的原因以及1年内TDM的次数。
研究期间共有200例患者接受了242种心境稳定剂治疗。研究人群中性别分布基本均衡,男性占52%,女性占48%。患者的平均年龄为40岁(范围为17 - 87岁)。共有41.5%(n = 83)的患者被诊断为双相I型障碍。丙戊酸(n = 139 [57.9%])和锂盐(n = 54 [22.3%])是最常用的心境稳定剂。大多数(80%)双相情感障碍患者使用单一心境稳定剂治疗。研究期间,200例患者共进行了613次TDM检测。研究期间每位患者TDM检测的平均次数为3次(范围为1 - 39次)。记录的TDM检测原因包括验证治疗水平(n = 140)、缺乏临床反应(n = 51)和剂量调整(n = 34)。
本研究突出了常规临床实践中心境稳定剂TDM检测的常见及特殊原因。需要在前瞻性基础上对更大样本量进行更广泛的研究,以确定TDM检测医嘱的合理性及其对制定相关政策的影响。